Preliminary recommendations made based on cases from the SOLAR-1 trial suggest that alpelisib-induced hyperglycemia can be managed with early detection, close monitoring, and prompt intervention.
Cost Analysis of Neratinib in an Extended Adjuvant Treatment Setting for Patients with Early-Stage, HR-Positive, HER2-Positive Breast Cancer
For patients with early HR-positive, HER2-positive breast cancer who initiated neratinib within 1 year of completing trastuzumab and in patients who did not achieve a pathologic complete response after neoadjuvant treatment, neratinib may be a cost-effective treatment option.
Effect of Multiple Certified Educational Activities on Knowledge and Competence with CDK4/6 Inhibitors in HR-Positive Breast Cancer
Participation in certified educational activities resulted in significant improvements in knowledge, competence, and confidence regarding the use of CDK4/6 inhibitor therapies in the management of patients with advanced HR-positive breast cancer.
Randomized Phase 3 Trial of Endocrine Therapy plus Entinostat in Patients with HR-Positive Advanced Breast Cancer
The combination of exemestane and entinostat did not show survival benefit in patients with aromatase inhibitor–resistant, HR-positive, HER2-negative advanced breast cancer.
Analysis of Ribociclib plus Letrozole in Male Patients with HR-Positive, HER2-Negative Advanced Breast Cancer
Subgroup analysis of the phase 3b CompLEEment-1 clinical trial supports the use of ribociclib combined with letrozole in HR-positive, HER2-negative advanced breast cancer male patients based on demonstrated efficacy and safety.
In a predominantly black, low-income population, women with diabetes and incident localized breast cancer had decreased overall survival when compared with those without diabetes.
Subgroup analysis of the phase 3b CompLEEment-1 clinical trial reinforces the efficacy and safety of ribociclib plus letrozole in premenopausal patients with HR-positive, HER2-negative advanced breast cancer.
Evaluation of an Alternative Schedule of Palbociclib in Patients with HR-Positive, HER2-Negative Metastatic Breast Cancer
An alternative schedule of palbociclib reduced grade ≥3 neutropenia and showed efficacy data comparable with previous reports.
Study of Adherence to and Patient Satisfaction with Exemestane and Everolimus in Postmenopausal Women with HR-Positive, HER2-Negative Advanced Breast Cancer
Findings from this study show that based on the adjusted adherence rate of the combination therapy of exemestane and everolimus, a low-rate adherence was observed.
Consistent with previous phase 3 studies with ribociclib and letrozole, few patients with HR-positive, HER2-negative advanced breast cancer and central nervous system metastases discontinued treatment due to side effects.
Web Exclusives | October 6, 2020
Deborah Toppmeyer, MD, and Jacquelyn Lauria, RN, MSN, of Rutgers CINJ, and Bob Gold of GoMo Health talk about the impact of Concierge Care at CINJ. This is their story.
The COVID-19 pandemic has created significant barriers to care, which can lead to increased mortality rates for thousands of patients with cancer. Nurses and nurse navigators are focused on using their skills and experience to combat this trend. Ongoing efforts include educating patients on the importance of undergoing cancer screenings, utilizing telehealth services to enhance communication with patients, addressing staffing shortages, and taking the necessary steps for preparing for potential spikes in COVID-19 cases.
Community oncology practices say they are recovering from the COVID-19 pandemic and keeping their eye on the goal of value-based care. The strategies they are using to accomplish these initiatives include innovation, long-term integration of telehealth, and the leveraging of advanced practice professionals.
It is a Herculean effort to develop a novel vaccine on an unprecedented timeline. Experts discuss the latest research regarding the development of vaccine candidates for the COVID-19 virus and some of the issues that will need to be addressed when a successful candidate has been identified, including clinical trial enrollment, manufacturing, and distribution.
Can the use of telehealth services help to address the upcoming burden of late cancer diagnoses, improve the co-management of chronic conditions, and give patients more power over their own health? During a recent AVBCC webinar, a panel of experts explored this question as they discussed the potential role of wearables, remote monitoring and communication, and other innovative technology for improving care for patients with cancer.
From the management of extended payment terms and performance-based agreements, to the potential impact of the proposed 2021 Medicare rules and the impending shortages of immune globulin, wholesale suppliers discuss how the COVID-19 pandemic continues to affect the oncology supply chain, what is being done to help practices, and what challenges lie ahead.
Although several of the financial indicators in oncology have recovered to pre-pandemic levels following dramatic declines that occurred earlier in the year, there are still significant challenges ahead. How will providers manage the backlog? What will happen to patients’ insurance coverage? How will oncology practices survive and thrive in a post–COVID-19 world?
Web Exclusives | August 18, 2020
Telehealth reimbursement. 340B. Drug pricing negotiations. There’s been a lot of action on healthcare-related proposals in Washington in recent weeks. What’s likely to last, and what is just “political theater”? AVBCC’s panel of experts has the inside scoop.
Web Exclusives | August 18, 2020
Initiatives to expand patient access programs, strategies to secure the supply chain, and updates on vaccine trials: leaders from top pharmaceutical manufacturers discussed their companies’ ongoing response to the worldwide pandemic in this AVBCC webcast.
Page 1 of 4
Results 1 - 30 of 103
Results 1 - 30 of 103